Drug-induced hemolytic anemia: Pharmacological aspects.

Details

Serval ID
serval:BIB_5FDB97D09073
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Drug-induced hemolytic anemia: Pharmacological aspects.
Journal
Transfusion clinique et biologique
Author(s)
Renard D., Rosselet A.
ISSN
1953-8022 (Electronic)
ISSN-L
1246-7820
Publication state
Published
Issued date
09/2017
Peer-reviewed
Oui
Volume
24
Number
3
Pages
110-114
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Drug-induced hemolytic anemia is a very rare but potentially lethal adverse drug reaction, which can take the form of oxidative damage to vulnerable erythrocytes (as in glucose-6-phosphate dehydrogenase deficiency), drug-induced thrombotic microangiopathy, or immune-mediated hemolytic anemia. For each form, distinctive drugs are documented as potential triggers. When a formal diagnosis of hemolytic anemia is made following drug administration, a structured approach is recommended to assess the plausibility of an adverse drug reaction based on chronological sequence, epidemiological data, objective evidence (when available), and ruling out of non-drug causes. For suspicions of immune-mediated hemolytic anemia, investigations by a laboratory with specific expertise are crucial given the complexity of the field. If there is good reason to believe hemolytic anemia is drug-induced, immediate drug discontinuation is necessary and corticosteroid administration can be considered. The clinical pharmacology specialist can support evaluation of drug imputability and report the case to the pharmacovigilance system, an important last step in managing such events.
Keywords
Adrenal Cortex Hormones/therapeutic use, Anemia, Hemolytic/chemically induced, Anemia, Hemolytic/epidemiology, Anemia, Hemolytic/etiology, Anemia, Hemolytic/physiopathology, Anemia, Hemolytic, Autoimmune/blood, Anemia, Hemolytic, Autoimmune/complications, Anti-Bacterial Agents/adverse effects, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Causality, Diagnosis, Differential, Disease Management, Disease Susceptibility, Glucosephosphate Dehydrogenase Deficiency/blood, Glucosephosphate Dehydrogenase Deficiency/complications, Humans, Osmotic Fragility, Oxidants/adverse effects, Oxidative Stress, Pharmacovigilance, Thrombotic Microangiopathies/blood, Thrombotic Microangiopathies/chemically induced, Anemia hemolytic, Anémie hémolytique, Drug hypersensitivity, Drug-related side effects and adverse reactions, Effet indésirable médicamenteux, Réaction d’hypersensibilité
Pubmed
Web of science
Create date
06/07/2017 17:54
Last modification date
20/08/2019 15:17
Usage data